• Explore /
  • Poster
  • / Bevacizumab (B) and erlotinib (E) as first-line therapy in metastatic non-squamous non-small cell lung cancer (NSCLC) followed by platinum-based chemotherapy (CT) at disease progression (PD): A multicenter phase II trial SAKK 19/05.

Bevacizumab (B) and erlotinib (E) as first-line therapy in metastatic non-squamous non-small cell lung cancer (NSCLC) followed by platinum-based chemotherapy (CT) at disease progression (PD): A multicenter phase II trial SAKK 19/05.

Abstract Poster

Authors

null

F. Zappa

Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

F. Zappa , C. Droege , D. C. Betticher , R. von Moos , M. H. Brutsche , F. Baty , L. Bubendorf , A. Ochsenbein , E. Oppliger Leibundgut , O. Gautschi , P. Froesch , R. A. Stahel , D. Rauch , P. Schmid , M. Mayer , S. Crowe , P. Brauchli , K. Ribi , M. Pless

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2011 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer - Metastatic/Non-small Cell

Track

Lung Cancer

Sub Track

Metastatic

Clinical Trial Registration Number

NCT00354549

Citation

J Clin Oncol 29: 2011 (suppl; abstr 7561)

Abstract #

7561

Poster Bd #

35A

Abstract Disclosures

Similar Posters

First Author: Wouter Willem Mellema

First Author: Rita Migliorino

First Author: Guru P. Sonpavde

First Author: Martin Reck